Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Sheryll Vincent

Allergy & Immunology Jackson, MS Medical Doctor

NPI 1063479723 CMS profile 320746

5440 Watkins Dr, Ste A, Jackson, MS 39206

Open in the dashboard

General payments

$2,667

68 records reported · program years 2019–2024

Research payments

$500

Paid to them · 1 record reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Sheryll Vincent of Jackson, MS is reported in the CMS Open Payments database as having received $2,667 across 68 general payments and $500 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $22 1
2023 General $656 19
2022 General $702 17
2021 General $356 15
2020 General $79 4
2019 General $852 12
2019 Research $500 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sheryll Vincent
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Sheryll Vincent were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Sheryll Vincent Allergy & Immunology median Middle half National median
2019 $852 $594 $163–$1,512 $163
2020 $79 $426 $106–$1,233 $114
2021 $356 $638 $157–$1,708 $132
2022 $702 $790 $205–$1,961 $149
2023 $656 $852 $220–$2,147 $160
2024 $22 $865 $203–$2,267 $164
2025 $0 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. GlaxoSmithKline, LLC. $1,056 16 payments
  2. AstraZeneca Pharmaceuticals LP $663 14 payments
  3. Regeneron Healthcare Solutions, Inc. $430 20 payments
  4. Pfizer Inc. $248 5 payments
  5. Genzyme Corporation $79 4 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $78 4 payments
  7. Uswm, LLC $57 2 payments
  8. Merck Sharp & Dohme Corporation $38 2 payments
  9. Genentech USA, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,592 66 payments
  2. Education $75 2 payments
Products named General payments · program years 2019–2024
  1. DUPIXENT $430 20 payments
  2. TRELEGY ELLIPTA $340 9 payments
  3. NUCALA Immunology $325 3 payments
  4. NUCALA Respiratory $267 3 payments
  5. FASENRA Respiratory $220 7 payments
  6. FASENRA Respiratory $179 3 payments
  7. EUCRISA $150 4 payments
  8. AREXVY $125 1 payment
  9. AIRSUPRA $108 2 payments
  10. CIBINQO $99 1 payment
  11. Other $299 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. LEO Pharma AS $500 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

407

Median for Pediatric Medicine: 38

Drug cost

$26,141

Median for Pediatric Medicine: $2,769

Branded share of claims

12%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $15,733
Levocetirizine Dihydrochloride Generic 102 $2,874
Epinephrine Generic 11 $2,725
Albuterol Sulfate Hfa Albuterol Sulfate Brand 37 $1,905
Montelukast Sodium Generic 100 $1,064
Fluticasone Propionate Generic 74 $904
Cromolyn Sodium Generic 27 $446
Azelastine Hcl Generic 12 $319
Triamcinolone Acetonide Generic 32 $170

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record